Tatva Chintan Pharma Chem ka Big Plan: FY27 mein **25%** Growth ka Target! Revenue **₹500 Cr** paar, ab kya hoga?

Naye expansion ka asar ab dikhne laga hai, bhai!

Company ne apna 30th anniversary celebrate karte hue FY26 mein ₹500 Crore ka revenue cross kiya. Q4 FY26 toh dhamakedar raha, Structure Directing Agents (SDA) ka revenue 52% bhaga aur Electrolyte Salts toh 1,378% upar chala gaya!

Asal mein, Dahej site par unka naya production block ab commercial scale par fully operational ho gaya hai. Management keh rahi hai ki ye ek 'inflection point' hai, jahan se company structured growth dikhayegi. FY27 ke liye toh 25% revenue growth aur 20-22% EBITDA margins ka target hai.

Ye kyu pakadna zaroori hai? (Why this matters)

Abhi tak company capacity banane mein zyada invest kar rahi thi, par ab time hai asli kamai ka. Nayi factories chalne se aur SDA, Electrolyte Salts jaise segments mein dumdaar demand se company market opportunities ko pakadne ke liye bilkul ready hai. FY27 ke liye jo growth aur margin projections hain, woh dikhate hain ki management apne expanded capacity ka poora fayda uthane ko confident hai.

Aage kya hai game plan mein? (What changes now)

Shareholders ko expect karna chahiye ki Dahej facility se FY27 tak revenue ₹850 se ₹900 Crore tak pahunch sakta hai. Aur toh aur, Jolva project jiska groundbreaking 60 din mein hoga, woh early 2028 tak ₹400 se ₹500 Crore ka revenue generate kar sakta hai. Plus, Pharma segment FY27 mein start ho jayega aur ₹70 se ₹75 Crore add karega. Hybrid battery applications ka commercial business bhi Q3 FY27 se chalu ho jayega.

Par risk bhi hain, bhai, kya pata? (Risks to watch)

• Raw Material ka Chakkar: Amine prices 30% se 40% badh gayi hain, aur company poora load customers par transfer nahi kar pa rahi, jo margins ke liye risk hai.
• Supply Chain Ka Lagaav: Global conflicts ke karan supply mein dikkatein aa rahi hain, March mein production days ka nuksan bhi hua.
• Naye Products Ka Time: Semiconductor ke liye validation mein time lag raha hai, actual commercialization late 2028 ya 2029 tak hoga.
• Tax Rate Ka Upar-Niche Hona: Q4 mein tax rate 38% tha jo short-term profit ko affect kar sakta hai.

Pichle numbers kaise the? (Context metrics)

• FY24 mein standalone revenue ₹392.7 crore tha, jo FY25 mein thoda badh kar ₹420.5 crore ho gaya.
• EBITDA margins FY24 mein 18.1% the, jo FY25 mein badh kar 19.2% ho gaye.

Investors ko kya follow karna chahiye? (What to track next)

• Jolva project ka groundbreaking aur construction timeline.
• FY27 mein Pharma segment aur battery applications se kitna revenue aata hai.
• Kya company raw material cost badhne ke baad bhi margins maintain kar paati hai.
• SDA segment mein demand ka trend, khaas kar Euro 7 norms ke baad.
• Semiconductor sector mein validation aur commercialization ka timeline.